Insulin glargine 300 U/mL in the management of diabetes: clinical utility and patient perspectives.

For any confirmed or severe hypoglycemia, ignoring the first 8 weeks, the treatments resulted in mild (ie, ~10%) risk reductions that often failed to reach statistical significance.

also in 6,035 other papers

Glargine-300 was associated with a lower rate of nocturnal hypoglycemia (glucose <3.9 mmol/L) compared to the other insulin products, although this difference did not reach statistical significance for degludec and detemir.

also in 111,027 other papers